Genetic Testing for Psychiatric Medications: What It Can and Can't Tell You

If you’re on your third or fourth antidepressant, you know how the cycle goes. One made you feel flat, another did nothing for two months, and now someone has mentioned a cheek-swab test that’s supposed to show which medication matches your DNA. After that much trial and error, a test that promises answers sounds like relief.

Here’s the biology underneath. Your liver breaks down many antidepressants with enzymes built from your genes, including two called CYP2D6 and CYP2C19. Common variations in those genes can make you break a drug down faster or slower than average, which changes how much of it stays in your blood. Pharmacogenomic (PGx) testing reads those genes, so its real strength is precision about drug levels and side effect risk rather than a forecast of whether a medication will lift your mood.

The established way to choose an antidepressant is clinical. A prescriber weighs your symptoms, history, other medications, and side effect concerns, starts a medication, then checks in and adjusts. That approach rests on solid ground: a 2018 network meta-analysis of 522 trials with 116,477 adults found that all 21 antidepressants studied worked better than placebo for major depression. The results are real, and the science is well established.

Genetic testing now adds real precision for a handful of gene-drug pairs, and at Siggy we’d rather show you exactly where that precision ends than let marketing decide it for you.

A PGx test is a one-time DNA test, usually a cheek swab or blood draw, that reports how your genes may affect the way your body handles specific medications. It targets the same problem careful prescribing does, finding a medication you can tolerate at a dose that works, with more precision for some drugs and little added information for others. Marketing often blurs the line between those two groups, so this guide draws it with the evidence.

What This Page Covers

• What Does Genetic Testing for Psychiatric Medications Measure?
• What Do the Biggest Trials Show?
• Why Are Psychiatry Experts Still Cautious?
• Where Does Genetic Testing Clearly Help?
• Who Might Benefit Most From Testing?
• What Should You Do With Results You Already Have?
• How Siggy Fits In
• The Bottom Line on Genetic Testing for Psychiatric Medications
• Start Your Anonymous Intake

What Does Genetic Testing for Psychiatric Medications Measure?

Most PGx panels focus on pharmacokinetic genes, the ones that shape what your body does to a drug. The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes gene-based prescribing guidelines, and its 2023 guideline found that variation in CYP2D6, CYP2C19, and CYP2B6 affects how many SSRIs and SNRIs are metabolized, which can influence dosing, effectiveness, and tolerability. Results usually place you in a category for each enzyme: poor, intermediate, normal, rapid, or ultrarapid metabolizer.

In plain terms, a poor metabolizer clears a drug slowly, so standard doses can build up and cause more side effects. An ultrarapid metabolizer clears it quickly, so a standard dose may never reach a helpful level.

Many commercial panels also report pharmacodynamic genes, which relate to how a drug acts on the brain, such as SLC6A4 (the serotonin transporter) and HTR2A (a serotonin receptor). The same CPIC guideline concluded that existing data don’t support using either gene in antidepressant prescribing.

Gene variation itself is nearly universal. In a UK Biobank analysis of 487,409 people, 99.5% carried variants in 14 well-studied genes that could cause an atypical response to at least one drug, psychiatric or otherwise. The same analysis found that people of non-European ancestry carry more potentially harmful variants that current test definitions often miss, so a test can overlook variants it wasn’t built to find.

What Do the Biggest Trials Show?

The short version is that test-guided care changes prescribing more reliably than it changes how people feel.

The GUIDED trial enrolled 1,167 outpatients with major depression who had an inadequate response to at least one antidepressant, then randomized them to care guided by a commercial combinatorial test (GeneSight) or usual care. At week 8, the primary outcome, average symptom improvement, wasn’t significantly different (27.2% vs. 24.4%). Response (26.0% vs. 19.9%) and remission (15.3% vs. 10.1%) were significantly better with the test. Several authors worked for the test’s maker.

The VA’s PRIME Care trial randomized 1,944 veterans starting or switching an antidepressant at 22 VA medical centers. Clinicians who had test results chose a medication with no predicted drug-gene interaction for an estimated 59% of patients, compared with 26% in usual care. Remission was modestly higher across 24 weeks, but the gap was no longer significant at week 24, and the authors called the effect on symptoms small and nonpersistent.

Pooled results point the same way. A 2022 meta-analysis of 13 trials and 4,767 patients found that test-guided treatment made remission about 1.4 times as likely, an increase the authors called modest. A 2026 meta-analysis of eight randomized trials found modest short-term gains in three trials of one test, while results across other multigene panels were inconsistent and imprecise. The authors cautioned that this doesn’t show one brand of test is better than another.

Here’s how those studies compare at a glance.

Study	Who Was Studied	Main Finding	Key Caveat
GUIDED trial, 2019	1,167 adults after a failed antidepressant	Primary outcome not significant, better response and remission	Authors tied to test maker
PRIME Care trial, 2022	1,944 veterans starting or switching	More gene-compatible prescribing, small remission gain	Gain not significant at 24 weeks
Meta-analysis, 2022	13 trials, 4,767 patients	Remission about 1.4 times as likely	Different tests across trials
Meta-analysis, 2026	8 randomized trials	Modest short-term gains for one test	Other panels inconsistent

Why Are Psychiatry Experts Still Cautious?

In 2024, an American Psychiatric Association workgroup updated its review of PGx tools for depression. Of 11 new clinical trials, only three showed a statistically significant benefit on their main outcome, and each used a different test. None used a fully blinded design, which matters because clinicians who know a patient’s results may treat that patient differently. The workgroup concluded, consistent with FDA advice, that the evidence doesn’t support using current combinatorial PGx tools to select treatment for major depressive disorder.

The FDA has also warned the public about pharmacogenetic tests that claim to predict a person’s response to a specific drug when those claims may not be supported by clinical evidence, according to the FDA’s consumer testing page.

Real-world data adds another layer. A 2026 health-system study of 1,563 people with depression who had psychiatric PGx testing found that prescribing shifted away from SSRIs most affected by CYP2C19 and CYP2D6. Psychiatric emergency visits didn’t differ significantly from matched controls overall, and hospitalization patterns didn’t change substantially. Black, American Indian or Alaska Native, and Asian, Native Hawaiian, or Pacific Islander patients also had 55% to 65% lower odds of being tested than white patients.

Where Does Genetic Testing Clearly Help?

Some gene-drug pairs are established enough to shape FDA guidance. The FDA’s pharmacogenetic associations table notes that people who are CYP2C19 poor metabolizers have higher citalopram (Celexa) levels and a higher risk of QT prolongation, a heart rhythm effect, so the maximum recommended dose is 20 mg. For CYP2D6 poor metabolizers, it lists 10 mg as the maximum recommended vortioxetine (Trintellix) dose and recommends dose adjustments for aripiprazole (Abilify) and brexpiprazole (Rexulti). Our guide to Celexa dosage covers how prescribers apply that limit.

Even here, the FDA says that listing a gene-drug pair doesn’t necessarily mean it recommends testing before prescribing, and that genetics is only one of many factors that affect drug levels and response.

Side effects may be where testing adds the most. The workgroup’s original 2018 review found insufficient data to support widespread use of combinatorial testing but noted clinical situations where it may be informative, particularly in predicting side effects.

Who Might Benefit Most From Testing?

No major psychiatric guideline recommends routine testing, so this is a decision to make with your prescriber. Testing tends to make the most sense when the result could change a specific choice:

• You’ve tried at least one antidepressant that didn’t help, which is the group the GUIDED trial studied.
• A medication caused side effects that felt out of proportion to the dose.
• Your prescriber is considering a drug with gene-based FDA dosing guidance, such as citalopram or vortioxetine.

Testing is less likely to change much if you’re starting your first antidepressant or a current medication is working well. Coverage and out-of-pocket costs vary by test and plan, so check with your insurer and the lab before you test. If you’re weighing a next step after several medications, our overview of treatment-resistant depression explains what counts as an adequate trial.

What Should You Do With Results You Already Have?

Bring them to your prescriber, and don’t act on them alone. The FDA’s table states that patients shouldn’t adjust their medications without consulting their prescriber, and the FDA’s consumer testing page notes that its authorized consumer pharmacogenetic report shouldn’t be used to start, stop, or change any treatment.

Reports often sort medications into categories. In GUIDED, for example, they ranged from “use as directed” to “use with increased caution and with more frequent monitoring.” A few principles help you read one:

• A “use as directed” result doesn’t mean a drug will work, and a flagged result doesn’t automatically rule one out. Your own history with a medication counts as evidence too.
• Your inherited genes don’t change, so results generally stay relevant, but different tests check different variants.
• Genetics is only one factor in how you process a drug, so other medications and health conditions still matter.

How Siggy Fits In

Siggy doesn’t order genetic tests today. Siggy’s licensed prescribers diagnose and treat the full range of mental health conditions, and they start with the information that drives most prescribing decisions: your symptoms, what you’ve tried, what helped, and what side effects you had.

The anonymous intake asks for no name, email, or account. If you’ve had PGx testing, mention the results along with your medication history, and a licensed prescriber reviews your full intake before anything is prescribed. Your downloadable summary means you won’t have to retell that history from scratch, whether you share it with Siggy’s prescribers or a clinician who orders testing later.

Siggy isn’t an emergency service. If you’re in crisis, call 911 or call or text 988. This article is for education only and isn’t a substitute for personal medical advice. It reflects sources available as of October 2026.

The Bottom Line on Genetic Testing for Psychiatric Medications

Genetic testing can tell you something real about how your body processes certain psychiatric medications, and for a few drugs that information directly changes dosing. It can’t yet reliably pick the antidepressant that will work for you, and the largest trials show modest, sometimes short-lived benefits. If you’ve been through several medications, testing is a reasonable question to raise alongside a careful review of what’s already been tried. Our guide to first-line vs. second-line antidepressants explains how prescribers choose a next step.

Start Your Anonymous Intake

If you’re in crisis right now, call 911 or call or text 988 first. If you’re tired of guessing at medications on your own, start your anonymous intake. It’s free, there’s no name or email required, and a licensed prescriber reviews your full intake, including your medication history, before anything is prescribed. Your summary is yours to keep and share, including with a clinician who orders genetic testing.